{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:20Z","timestamp":1792724780222,"version":"4.5.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed\/refractory (R\/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma (MM). However, this type of therapy has faced serious hindrances in combating T-cell neoplasms. R\/R T-cell malignancies are generally associated with poor clinical outcomes, and the available effective treatment approaches are very limited. CAR-T therapy of T-cell malignancies has unique impediments in comparison with that of B-cell malignancies. Fratricide, T-cell aplasia, and product contamination with malignant T cells when producing autologous CAR-Ts are the most important challenges of CAR-T therapy in T-cell malignancies necessitating in-depth investigations. Herein, we highlight the preclinical and clinical efforts made for addressing these drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T-cell malignancies.\n<\/jats:p>","DOI":"10.1186\/s13287-021-02595-0","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T12:37:17Z","timestamp":1633610237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["CAR-T cell\u00a0therapy in T-cell malignancies: Is success a low-hanging fruit?"],"prefix":"10.1186","volume":"12","author":[{"given":"Pouya","family":"Safarzadeh Kozani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooria","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-8366","authenticated-orcid":false,"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"3","key":"2595_CR1","first-page":"166","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(3):166.","journal-title":"Nat Rev Drug Discov"},{"key":"2595_CR2","doi-asserted-by":"crossref","unstructured":"FDA Approves Second CAR T-cell Therapy. Cancer Discov. 2018;8(1):5\u20136.","DOI":"10.1158\/2159-8290.CD-NB2017-155"},{"issue":"10","key":"2595_CR3","first-page":"669","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16(10):669.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2595_CR4","first-page":"832","volume":"324","author":"R Voelker","year":"2020","unstructured":"Voelker R. CAR-T therapy is approved for mantle cell lymphoma. JAMA. 2020;324(9):832.","journal-title":"JAMA"},{"issue":"5","key":"2595_CR5","first-page":"332","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(5):332.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2595_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevImmunol.2020036178","volume":"41","author":"J Chen","year":"2021","unstructured":"Chen J, Jiang H. Current challenges and strategies for chimeric antigen receptor-T-cell therapy for solid tumors. Crit Rev Immunol. 2021;41(1):1\u201312.","journal-title":"Crit Rev Immunol"},{"issue":"9","key":"2595_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood-2017-01-741389","volume":"129","author":"LH Sehn","year":"2017","unstructured":"Sehn LH, Soulier J. Introduction to the review series on T-cell malignancies. Blood. 2017;129(9):1059\u201360.","journal-title":"Blood"},{"issue":"1","key":"2595_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","volume":"1","author":"B Coiffier","year":"1990","unstructured":"Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Agressives). Ann Oncol. 1990;1(1):45\u201350.","journal-title":"Ann Oncol"},{"issue":"25","key":"2595_CR9","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2595_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","volume":"77","author":"D Campana","year":"1991","unstructured":"Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K, et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood. 1991;77(7):1546\u201354.","journal-title":"Blood"},{"issue":"3","key":"2595_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"4","key":"2595_CR12","first-page":"331","volume":"19","author":"GD Sempowski","year":"1999","unstructured":"Sempowski GD, Lee DM, Kaufman RE, Haynes BF. Structure and function of the CD7 molecule. Crit Rev Immunol. 1999;19(4):331\u201348.","journal-title":"Crit Rev Immunol"},{"issue":"2","key":"2595_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/blood.V82.2.343.343","volume":"82","author":"CH Pui","year":"1993","unstructured":"Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82(2):343\u201362.","journal-title":"Blood"},{"issue":"4","key":"2595_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bjh.12042","volume":"159","author":"JL Patel","year":"2012","unstructured":"Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children\u2019s Oncology Group report. Br J Haematol. 2012;159(4):454\u201361.","journal-title":"Br J Haematol"},{"key":"2595_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1146\/annurev.immunol.20.100301.064833","volume":"20","author":"R Berland","year":"2002","unstructured":"Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol. 2002;20:253\u2013300.","journal-title":"Annu Rev Immunol"},{"issue":"6086","key":"2595_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/323346a0","volume":"323","author":"NH Jones","year":"1986","unstructured":"Jones NH, Clabby ML, Dialynas DP, Huang HJ, Herzenberg LA, Strominger JL. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1\/Leu-1. Nature. 1986;323(6086):346\u20139.","journal-title":"Nature"},{"issue":"2","key":"2595_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/138945009787354539","volume":"10","author":"AE Frankel","year":"2009","unstructured":"Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets. 2009;10(2):104\u20139.","journal-title":"Curr Drug Targets"},{"issue":"49","key":"2595_CR18","doi-asserted-by":"publisher","first-page":"17576","DOI":"10.1073\/pnas.1420936111","volume":"111","author":"ME Birnbaum","year":"2014","unstructured":"Birnbaum ME, Berry R, Hsiao Y-S, Chen Z, Shingu-Vazquez MA, Yu X, et al. Molecular architecture of the \u03b1\u03b2 T cell receptor\u2013CD3 complex. Proc Natl Acad Sci. 2014;111(49):17576\u201381.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"2595_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM199902183400703","volume":"340","author":"RH Buckley","year":"1999","unstructured":"Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"2595_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/35105066","volume":"1","author":"WJ Leonard","year":"2001","unstructured":"Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol. 2001;1(3):200\u20138.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2595_CR21","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970\u201383.","journal-title":"Leukemia"},{"issue":"3","key":"2595_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.yexmp.2007.08.012","volume":"83","author":"JL Suggs","year":"2007","unstructured":"Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol. 2007;83(3):471\u20133.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"2595_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5045\/br.2020.55.1.10","volume":"55","author":"E Fathi","year":"2020","unstructured":"Fathi E, Farahzadi R, Sheervalilou R, Sanaat Z, Vietor I. A general view of CD33(+) leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy. Blood Res. 2020;55(1):10\u20136.","journal-title":"Blood Res"},{"key":"2595_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-0716-0146-4_4","volume":"2086","author":"MG Lana","year":"2020","unstructured":"Lana MG, Strauss BE. Production of Lentivirus for the Establishment of CAR-T Cells. Methods Mol Biol. 2020;2086:61\u20137.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2595_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/hum.2018.145","volume":"30","author":"JB Foster","year":"2019","unstructured":"Foster JB, Choudhari N, Perazzelli J, Storm J, Hofmann TJ, Jain P, et al. Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response. Hum Gene Ther. 2019;30(2):168\u201378.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2595_CR26","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.tranon.2021.101079","volume":"14","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Novel antigens of CAR T cell therapy: new roads; old destination. Transl Oncol. 2021;14(7):101079.","journal-title":"Transl Oncol"},{"issue":"7","key":"2595_CR27","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1158\/1535-7163.MCT-20-1089","volume":"20","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, O\u2019Connor RS. In like a lamb; out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL. Mol Cancer Ther. 2021;20(7):1223\u201333.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2595_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12032-020-01416-3","volume":"37","author":"M Hashem Boroojerdi","year":"2020","unstructured":"Hashem Boroojerdi M, Rahbarizadeh F, Safarzadeh Kozani P, Kamali E, Safarzadeh KP. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Med Oncol. 2020;37(11):100.","journal-title":"Med Oncol"},{"issue":"4","key":"2595_CR29","first-page":"502","volume":"22","author":"A Rajabzadeh","year":"2021","unstructured":"Rajabzadeh A, Rahbarizadeh F, Ahmadvand D, Kabir Salmani M, Hamidieh AA. A VHH-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells. Cell J. 2021;22(4):502\u201313.","journal-title":"Cell J"},{"issue":"4","key":"2595_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12185-012-1037-6","volume":"95","author":"S Khaleghi","year":"2012","unstructured":"Khaleghi S, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Pognonec P. A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int J Hematol. 2012;95(4):434\u201344.","journal-title":"Int J Hematol"},{"issue":"1","key":"2595_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbagen.2013.09.029","volume":"1840","author":"FR Jamnani","year":"2014","unstructured":"Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, et al. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. Biochim Biophys Acta. 2014;1840(1):378\u201386.","journal-title":"Biochim Biophys Acta"},{"key":"2595_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","volume":"141","author":"F Rahbarizadeh","year":"2019","unstructured":"Rahbarizadeh F, Ahmadvand D, Moghimi SM. CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019;141:41\u20136.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2595_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","volume":"334","author":"Z Sharifzadeh","year":"2013","unstructured":"Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, et al. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 2013;334(2):237\u201344.","journal-title":"Cancer Lett"},{"issue":"16","key":"2595_CR34","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci USA. 2019;116(16):7624\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2595_CR35","doi-asserted-by":"crossref","unstructured":"Wang D, Starr R, Chang WC, Aguilar B, Alizadeh D, Wright SL, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020;12(533).","DOI":"10.1126\/scitranslmed.aaw2672"},{"issue":"924","key":"2595_CR36","doi-asserted-by":"publisher","first-page":"627549","DOI":"10.3389\/fonc.2021.627549","volume":"11","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Khoshtinat NS. Strategies for Dodging the obstacles in CAR T cell therapy. Front Oncol. 2021;11(924):627549.","journal-title":"Front Oncol"},{"issue":"1","key":"2595_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"2","key":"2595_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44(2):412\u20138.","journal-title":"Biochem Soc Trans"},{"issue":"7","key":"2595_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499\u2013509.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2595_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4\u20131BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413\u201320.","journal-title":"Mol Ther"},{"issue":"21","key":"2595_CR41","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood.V116.21.2088.2088","volume":"116","author":"J Duell","year":"2010","unstructured":"Duell J, Lurati S, Dittrich M, Bedke T, Pule M, Einsele H, et al. First generation chimeric antigen receptor display functional defects in key signal pathways upon antigen stimulation. Blood. 2010;116(21):2088.","journal-title":"Blood"},{"issue":"3","key":"2595_CR42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"2595_CR43","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3324\/haematol.2015.123711","volume":"100","author":"AE Frankel","year":"2015","unstructured":"Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, et al. Resimmune, an anti-CD3\u03b5 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015;100(6):794\u2013800.","journal-title":"Haematologica"},{"issue":"35","key":"2595_CR44","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016;7(35):56219\u201332.","journal-title":"Oncotarget"},{"key":"2595_CR45","doi-asserted-by":"crossref","unstructured":"Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3(13).","DOI":"10.1172\/jci.insight.99442"},{"issue":"13","key":"2595_CR46","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1182\/blood-2002-05-1525","volume":"100","author":"H Gary-Gouy","year":"2002","unstructured":"Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100(13):4537\u201343.","journal-title":"Blood"},{"issue":"7","key":"2595_CR47","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.4049\/jimmunol.179.7.4335","volume":"179","author":"H Gary-Gouy","year":"2007","unstructured":"Gary-Gouy H, Sainz-Perez A, Marteau JB, Marfaing-Koka A, Delic J, Merle-Beral H, et al. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol. 2007;179(7):4335\u201344.","journal-title":"J Immunol"},{"issue":"4","key":"2595_CR48","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1128\/MCB.19.4.2903","volume":"19","author":"JJ Perez-Villar","year":"1999","unstructured":"Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol. 1999;19(4):2903\u201312.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2595_CR49","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood.V68.3.752.752","volume":"68","author":"JH Bertram","year":"1986","unstructured":"Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, et al. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood. 1986;68(3):752\u201361.","journal-title":"Blood"},{"issue":"5","key":"2595_CR50","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1182\/blood.V78.5.1173.1173","volume":"78","author":"CF LeMaistre","year":"1991","unstructured":"LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood. 1991;78(5):1173\u201382.","journal-title":"Blood"},{"issue":"8","key":"2595_CR51","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell\u2013directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983\u201392.","journal-title":"Blood"},{"issue":"10","key":"2595_CR52","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"KH Chen","year":"2017","unstructured":"Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31(10):2151\u201360.","journal-title":"Leukemia"},{"issue":"3","key":"2595_CR53","doi-asserted-by":"publisher","first-page":"e1407898","DOI":"10.1080\/2162402X.2017.1407898","volume":"7","author":"SS Raikar","year":"2018","unstructured":"Raikar SS, Fleischer LC, Moot R, Fedanov A, Paik NY, Knight KA, et al. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. OncoImmunology. 2018;7(3):e1407898.","journal-title":"OncoImmunology."},{"issue":"1","key":"2595_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","volume":"6","author":"M Mamonkin","year":"2018","unstructured":"Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, et al. Reversible transgene expression reduces fratricide and permits 4\u20131BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6(1):47\u201358.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2595_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","volume":"12","author":"Y Xu","year":"2019","unstructured":"Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019;12(1):49.","journal-title":"J Hematol Oncol"},{"issue":"3\u20134","key":"2595_CR56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/10428199709051778","volume":"26","author":"AE Frankel","year":"1997","unstructured":"Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma. 1997;26(3\u20134):287\u201398.","journal-title":"Leuk Lymphoma"},{"key":"2595_CR57","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2147\/IJN.S127575","volume":"12","author":"Y Yu","year":"2017","unstructured":"Yu Y, Li J, Zhu X, Tang X, Bao Y, Sun X, et al. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomed. 2017;12:1969\u201383.","journal-title":"Int J Nanomed"},{"issue":"25","key":"2595_CR58","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1(25):2348\u201360.","journal-title":"Blood Adv"},{"issue":"9","key":"2595_CR59","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970\u201383.","journal-title":"Leukemia"},{"issue":"1","key":"2595_CR60","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9(1):64\u201378.","journal-title":"Am J Cancer Res"},{"key":"2595_CR61","doi-asserted-by":"crossref","unstructured":"Zhang M, Yang L, Fu X, Zhang L, Meng H, Li L, et al. First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory ACUTE lymphoblastic leukemia\/lymphoma. J Clin Oncol. 2020;38(15_suppl):3026.","DOI":"10.1200\/JCO.2020.38.15_suppl.3026"},{"issue":"1","key":"2595_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0145-2126(98)00133-7","volume":"23","author":"R Burger","year":"1999","unstructured":"Burger R, Hansen-Hagge TE, Drexler HG, Gramatzki M. Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies. Leuk Res. 1999;23(1):19\u201327.","journal-title":"Leuk Res"},{"issue":"4","key":"2595_CR63","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/sj.leu.2401382","volume":"13","author":"T Niehues","year":"1999","unstructured":"Niehues T, Kapaun P, Harms DO, Burdach S, Kramm C, K\u00f6rholz D, et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia. 1999;13(4):614\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"2595_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.leu.2404957","volume":"22","author":"M van Grotel","year":"2008","unstructured":"van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia. 2008;22(1):124\u201331.","journal-title":"Leukemia"},{"issue":"21","key":"2595_CR65","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez D, Baroni ML, Gutierrez-Ag\u00fcera F, Roca-Ho H, Blanch-Lombarte O, Gonz\u00e1lez-Garc\u00eda S, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133(21):2291\u2013304.","journal-title":"Blood"},{"issue":"5","key":"2595_CR66","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","volume":"150","author":"F d'Amore","year":"2010","unstructured":"d\u2019Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol. 2010;150(5):565\u201373.","journal-title":"Br J Haematol"},{"issue":"2","key":"2595_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1385\/MO:22:2:191","volume":"22","author":"H Hagberg","year":"2005","unstructured":"Hagberg H, Pettersson M, Bjerner T, Enblad G. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol. 2005;22(2):191\u20134.","journal-title":"Med Oncol"},{"issue":"11","key":"2595_CR68","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","volume":"109","author":"YH Kim","year":"2007","unstructured":"Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109(11):4655\u201362.","journal-title":"Blood"},{"issue":"3","key":"2595_CR69","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","volume":"87","author":"S Knox","year":"1996","unstructured":"Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996;87(3):893\u20139.","journal-title":"Blood"},{"issue":"3","key":"2595_CR70","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/leu.2015.311","volume":"30","author":"K Pinz","year":"2016","unstructured":"Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia. 2016;30(3):701\u20137.","journal-title":"Leukemia"},{"issue":"68","key":"2595_CR71","doi-asserted-by":"publisher","first-page":"112783","DOI":"10.18632\/oncotarget.22626","volume":"8","author":"KG Pinz","year":"2017","unstructured":"Pinz KG, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH, et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 2017;8(68):112783\u201396.","journal-title":"Oncotarget"},{"issue":"11","key":"2595_CR72","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","volume":"32","author":"M Alcantara","year":"2018","unstructured":"Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. 2018;32(11):2307\u201315.","journal-title":"Leukemia"},{"issue":"3","key":"2595_CR73","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","volume":"15","author":"G Ma","year":"2019","unstructured":"Ma G, Shen J, Pinz K, Wada M, Park J, Kim S, et al. Targeting T cell malignancies using CD4CAR T-cells and implementing a natural safety switch. Stem Cell Rev Rep. 2019;15(3):443\u20137.","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"2595_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","volume":"85","author":"B Falini","year":"1995","unstructured":"Falini B, Pileri S, Pizzolo G, D\u00fcrkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1\u201314.","journal-title":"Blood"},{"issue":"3","key":"2595_CR75","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3109\/10428194.2013.820293","volume":"55","author":"W Zheng","year":"2014","unstructured":"Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014;55(3):624\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2595_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2019.1558399","volume":"12","author":"C Van Der Weyden","year":"2019","unstructured":"Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol. 2019;12(1):5\u201319.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2595_CR77","first-page":"1116","volume":"58","author":"A Hombach","year":"1998","unstructured":"Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin\u2019s lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58(6):1116\u20139.","journal-title":"Cancer Res"},{"issue":"6","key":"2595_CR78","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00002371-199911000-00001","volume":"22","author":"A Hombach","year":"1999","unstructured":"Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin\u2019s lymphoma-associated CD30 antigen. J Immunother. 1999;22(6):473\u201380.","journal-title":"J Immunother"},{"issue":"9","key":"2595_CR79","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Investig. 2017;127(9):3462\u201371.","journal-title":"J Clin Investig"},{"issue":"5","key":"2595_CR80","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"C-M Wang","year":"2017","unstructured":"Wang C-M, Wu Z-Q, Wang Y, Guo Y-L, Dai H-R, Wang X-H, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"key":"2595_CR81","doi-asserted-by":"crossref","unstructured":"Park SI, Serody JS, Shea TC, Grover NS, Ivanova A, Morrison K, et al. A phase 1b\/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2017;35(15_suppl):TPS3095-TPS.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3095"},{"issue":"32","key":"2595_CR82","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2595_CR83","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.4049\/jimmunol.172.5.2953","volume":"172","author":"AB van Spriel","year":"2004","unstructured":"van Spriel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z, et al. A regulatory role for CD37 in T cell proliferation. J Immunol. 2004;172(5):2953\u201361.","journal-title":"J Immunol"},{"issue":"5","key":"2595_CR84","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694\u2013708.","journal-title":"Cancer Cell"},{"issue":"8","key":"2595_CR85","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","volume":"19","author":"S Barrena","year":"2005","unstructured":"Barrena S, Almeida J, Yunta M, L\u00f3pez A, Fern\u00e1ndez-Mosteir\u00edn N, Giralt M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia. 2005;19(8):1376\u201383.","journal-title":"Leukemia"},{"issue":"7","key":"2595_CR86","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","volume":"14","author":"DS Pereira","year":"2015","unstructured":"Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, et al. AGS67E, an anti-CD37 Monomethyl Auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. 2015;14(7):1650\u201360.","journal-title":"Mol Cancer Ther"},{"key":"2595_CR87","doi-asserted-by":"crossref","unstructured":"Sawas A, Savage KJ, Perez RP, Advani RH, Zaine JM, Lackey JM, et al. A Phase 1 Study of the Anti-CD37 Antibody-drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results. Hematol Oncol. 2017;35(S2):49.","DOI":"10.1002\/hon.2437_32"},{"issue":"14","key":"2595_CR88","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarf\u00f2","year":"2018","unstructured":"Scarf\u00f2 I, Ormh\u00f8j M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018;132(14):1495\u2013506.","journal-title":"Blood"},{"issue":"3","key":"2595_CR89","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11899-012-0124-3","volume":"7","author":"K Tobinai","year":"2012","unstructured":"Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep. 2012;7(3):235\u201340.","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"2595_CR90","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","volume":"119","author":"K Ferenczi","year":"2002","unstructured":"Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Investig Dermatol. 2002;119(6):1405\u201310.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"2595_CR91","first-page":"3625","volume":"9","author":"T Ishida","year":"2003","unstructured":"Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma. Its Close Assoc Skin Involv Unfavorable Outcome. 2003;9(10):3625\u201334.","journal-title":"Its Close Assoc Skin Involv Unfavorable Outcome"},{"issue":"6","key":"2595_CR92","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1346-8138.12852","volume":"42","author":"M Sugaya","year":"2015","unstructured":"Sugaya M, Morimura S, Suga H, Kawaguchi M, Miyagaki T, Ohmatsu H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol. 2015;42(6):613\u20135.","journal-title":"J Dermatol"},{"issue":"4","key":"2595_CR93","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/1060028019884863","volume":"54","author":"DC Moore","year":"2020","unstructured":"Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell lymphomas. Ann Pharmacother. 2020;54(4):371\u20139.","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2595_CR94","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.24794","volume":"92","author":"LP Perera","year":"2017","unstructured":"Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol. 2017;92(9):892\u2013901.","journal-title":"Am J Hematol"},{"issue":"8","key":"2595_CR95","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2595_CR96","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cas.12116","volume":"104","author":"T Ishida","year":"2013","unstructured":"Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma. Cancer Sci. 2013;104(5):647\u201350.","journal-title":"Cancer Sci"},{"issue":"11","key":"2595_CR97","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2595_CR98","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood.V75.1.174.174","volume":"75","author":"CH Pui","year":"1990","unstructured":"Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood. 1990;75(1):174\u20139.","journal-title":"Blood"},{"key":"2595_CR99","doi-asserted-by":"crossref","unstructured":"Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol. 2001;116(4):512\u201326.","DOI":"10.1309\/QF6N-VAQW-N74H-4JE2"},{"issue":"16","key":"2595_CR100","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2595_CR101","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370.","journal-title":"Nat Genet"},{"issue":"15","key":"2595_CR102","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1073\/pnas.82.15.5068","volume":"82","author":"A Tunnacliffe","year":"1985","unstructured":"Tunnacliffe A, Kefford R, Milstein C, Forster A, Rabbitts TH. Sequence and evolution of the human T-cell antigen receptor beta-chain genes. Proc Natl Acad Sci USA. 1985;82(15):5068\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2595_CR103","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416\u201323.","journal-title":"Nat Med"},{"issue":"1","key":"2595_CR104","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","volume":"28","author":"LT Morton","year":"2020","unstructured":"Morton LT, Reijmers RM, Wouters AK, Kweekel C, Remst DFG, Pothast CR, et al. Simultaneous deletion of endogenous TCR\u03b1\u03b2 for TCR gene therapy creates an improved and safe cellular therapeutic. Mol Ther. 2020;28(1):64\u201374.","journal-title":"Mol Ther"},{"key":"2595_CR105","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187.","journal-title":"J Immunol Res"},{"issue":"18","key":"2595_CR106","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"2595_CR107","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","volume":"18","author":"S Yu","year":"2019","unstructured":"Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18(1):125.","journal-title":"Mol Cancer"},{"issue":"11","key":"2595_CR108","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1182\/blood-2006-04-015230","volume":"109","author":"C Traversari","year":"2007","unstructured":"Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109(11):4708\u201315.","journal-title":"Blood"},{"issue":"10","key":"2595_CR109","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","volume":"132","author":"J Svoboda","year":"2018","unstructured":"Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, et al. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. Blood. 2018;132(10):1022\u20136.","journal-title":"Blood"},{"issue":"12","key":"2595_CR110","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1089\/hum.2011.070","volume":"22","author":"DM Barrett","year":"2011","unstructured":"Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 2011;22(12):1575\u201386.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"2595_CR111","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/cgt.2008.98","volume":"16","author":"SH Yoon","year":"2009","unstructured":"Yoon SH, Lee JM, Cho HI, Kim EK, Kim HS, Park MY, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2\/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 2009;16(6):489\u201397.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"2595_CR112","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/gt.2008.189","volume":"16","author":"K Birkholz","year":"2009","unstructured":"Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, K\u00e4mpgen E, et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009;16(5):596\u2013604.","journal-title":"Gene Ther"},{"issue":"10","key":"2595_CR113","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503.","journal-title":"Nat Med"},{"issue":"16","key":"2595_CR114","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"2595_CR115","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","volume":"126","author":"MR Litzow","year":"2015","unstructured":"Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126(7):833\u201341.","journal-title":"Blood"},{"issue":"25","key":"2595_CR116","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114(25):5136\u201345.","journal-title":"Blood"},{"issue":"9","key":"2595_CR117","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134\u201342.","journal-title":"Blood"},{"issue":"3","key":"2595_CR118","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"2595_CR119","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","volume":"11","author":"MA Morgan","year":"2020","unstructured":"Morgan MA, B\u00fcning H, Sauer M, Schambach A. Use of cell and genome modification technologies to generate improved \u201cOff-the-Shelf\u201d CAR T and CAR NK Cells. Front Immunol. 2020;11:1965.","journal-title":"Front Immunol"},{"issue":"24","key":"2595_CR120","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu P-Q, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697\u2013705.","journal-title":"Blood"},{"key":"2595_CR121","doi-asserted-by":"crossref","unstructured":"Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.","DOI":"10.1126\/scitranslmed.3008825"},{"key":"2595_CR122","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","volume":"8","author":"A Houghtelin","year":"2017","unstructured":"Houghtelin A, Bollard CM. Virus-Specific T Cells for the Immunocompromised Patient. Front Immunol. 2017;8:1272.","journal-title":"Front Immunol"},{"issue":"22","key":"2595_CR123","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","volume":"116","author":"JJ Melenhorst","year":"2010","unstructured":"Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700\u20132.","journal-title":"Blood"},{"issue":"12","key":"2595_CR124","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nri.2017.101","volume":"17","author":"MM Nielsen","year":"2017","unstructured":"Nielsen MM, Witherden DA, Havran WL. \u03b3\u03b4 T cells in homeostasis and host defence of epithelial barrier tissues. Nat Rev Immunol. 2017;17(12):733\u201345.","journal-title":"Nat Rev Immunol"},{"key":"2595_CR125","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fimmu.2018.00985","volume":"9","author":"NE McCarthy","year":"2018","unstructured":"McCarthy NE, Eberl M. Human \u03b3\u03b4 T-Cell Control of Mucosal Immunity and Inflammation. Front Immunol. 2018;9:985.","journal-title":"Front Immunol"},{"issue":"12","key":"2595_CR126","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood-2009-08-237123","volume":"115","author":"T Lan\u00e7a","year":"2010","unstructured":"Lan\u00e7a T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia\/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood. 2010;115(12):2407\u201311.","journal-title":"Blood"},{"issue":"2","key":"2595_CR127","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.bbrc.2007.01.031","volume":"354","author":"R Uchida","year":"2007","unstructured":"Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun. 2007;354(2):613\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2595_CR128","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.4049\/jimmunol.0900101","volume":"182","author":"J Li","year":"2009","unstructured":"Li J, Herold MJ, Kimmel B, M\u00fcller I, Rincon-Orozco B, Kunzmann V, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol. 2009;182(12):8118\u201324.","journal-title":"J Immunol"},{"issue":"1","key":"2595_CR129","first-page":"37","volume":"58","author":"I Nagamine","year":"2009","unstructured":"Nagamine I, Yamaguchi Y, Ohara M, Ikeda T, Okada M. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Hiroshima J Med Sci. 2009;58(1):37\u201344.","journal-title":"Hiroshima J Med Sci"},{"key":"2595_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4419-1050-9_2","volume":"658","author":"K Thompson","year":"2010","unstructured":"Thompson K, Roelofs AJ, Jauhiainen M, M\u00f6nkk\u00f6nen H, M\u00f6nkk\u00f6nen J, Rogers MJ. Activation of \u03b3\u03b4 T cells by bisphosphonates. Adv Exp Med Biol. 2010;658:11\u201320.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"2595_CR131","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric Antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018;26(2):354\u201365.","journal-title":"Mol Ther"},{"issue":"4","key":"2595_CR132","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","volume":"126","author":"M Rischer","year":"2004","unstructured":"Rischer M, Pscherer S, Duwe S, Vormoor J, J\u00fcrgens H, Rossig C. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126(4):583\u201392.","journal-title":"Br J Haematol"},{"issue":"1","key":"2595_CR133","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12885-017-3539-3","volume":"17","author":"DC Harrer","year":"2017","unstructured":"Harrer DC, Simon B, Fujii SI, Shimizu K, Uslu U, Schuler G, et al. RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: a safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma. BMC Cancer. 2017;17(1):551.","journal-title":"BMC Cancer"},{"key":"2595_CR134","doi-asserted-by":"crossref","unstructured":"Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6(21).","DOI":"10.3389\/fphar.2015.00021"},{"key":"2595_CR135","doi-asserted-by":"crossref","unstructured":"Simonetta F, Alvarez M, Negrin RS. Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation. Front Immunol. 2017;8(465).","DOI":"10.3389\/fimmu.2017.00465"},{"key":"2595_CR136","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","volume":"20","author":"DSJ Allan","year":"2021","unstructured":"Allan DSJ, Chakraborty M, Waller GC, Hochman MJ, Poolcharoen A, Reger RN, et al. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Mol Ther Methods Clin Dev. 2021;20:559\u201371.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"2595_CR137","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jcyt.2020.06.003","volume":"22","author":"Q Liu","year":"2020","unstructured":"Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y, et al. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model. Cytotherapy. 2020;22(10):552\u201362.","journal-title":"Cytotherapy"},{"key":"2595_CR138","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.","journal-title":"Front Immunol"},{"issue":"3","key":"2595_CR139","doi-asserted-by":"publisher","first-page":"e28092","DOI":"10.1002\/pbc.28092","volume":"67","author":"DE Arnold","year":"2020","unstructured":"Arnold DE, Maude SL, Callahan CA, DiNofia AM, Grupp SA, Heimall JR. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients. Pediatr Blood Cancer. 2020;67(3):e28092.","journal-title":"Pediatr Blood Cancer"},{"key":"2595_CR140","doi-asserted-by":"crossref","unstructured":"Misbah SA, Weeratunga P. Immunoglobulin replacement and quality of life after CAR T-cell therapy. Lancet Oncol. 2020;21(1):e6.","DOI":"10.1016\/S1470-2045(19)30782-X"},{"issue":"3","key":"2595_CR141","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2595_CR142","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","volume":"11","author":"J Zhao","year":"2018","unstructured":"Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132.","journal-title":"J Hematol Oncol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02595-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T14:53:22Z","timestamp":1706194402000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02595-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"527"}}